See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Wrestling
Soccer
Donald Trump
Elon Musk
CPAC
Baseball
Hamas
Vatican
Everton
Israel-Hamas Conflict
Published • loading... • Updated

Bimekizumab Long-Term Hidradenitis Suppurativa Data Support Efficacy, Safety Profile

Summary by hcplive.com
New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
hcplive.comhcplive.com

Bimekizumab Long-Term Hidradenitis Suppurativa Data Support Efficacy, Safety Profile

New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.

Read Full Article
pharmatimes.compharmatimes.com

Bimekizumab shows long-term efficacy in hidradenitis suppurativa

UCB's BIMZELX reveals promising two-year data at EHSF 2025

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmatimes.com broke the news in on Wednesday, February 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Francisco, California

San Francisco, California

News
For You
Search
BlindspotLocal